Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn’s disease and cancer drugs Darzalex and Imbruvica.
Source:: Reuters – Business News
